{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:39:22Z","timestamp":1788932362733,"version":"build-2803163510"},"reference-count":30,"publisher":"Korean Cancer Association","issue":"1","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2022-NR070625"],"award-info":[{"award-number":["RS-2022-NR070625"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["e-crt.org"],"crossmark-restriction":true},"short-container-title":["Cancer Res Treat"],"published-print":{"date-parts":[[2026,1,15]]},"abstract":"<jats:p>PurposeThis retrospective study evaluated the efficacy and safety of a weekly carfilzomib, cyclophosphamide, and dexamethasone (KCd) regimen in patients with relapsed or refractory multiple myeloma (RRMM) who had been previously treated with both bortezomib- and lenalidomide-containing regimens.Materials and MethodsWe conducted a retrospective analysis of 33 patients with RRMM who received the KCd regimen between March 2020 and February 2024. All patients had prior exposure to both bortezomib and lenalidomide, and the majority (93.9%) were refractory to lenalidomide. Carfilzomib was administered once weekly at 70 mg\/m&lt;sup&gt;2&lt;\/sup&gt; (after a step-up dose), along with oral cyclophosphamide and dexamethasone. Treatment response was assessed according to the International Myeloma Working Group criteria, and survival outcomes were analyzed.Results The overall response rate was 66.7%, including a complete response or better in 15.1% of patients and a very good partial response or better in 42.4%. With a median follow-up of 31.7 months, the median progression-free survival was 13.5 months (95% confidence interval, 11.47 to 15.53), while the median overall survival was not reached. The most common grade \u2265 3 adverse event was neutropenia (15.2%). Non-hematologic grade \u2265 3 toxicities were infrequent and manageable.ConclusionThe weekly KCd regimen demonstrated encouraging efficacy and tolerability in a heavily pretreated RRMM population. These findings support its use as a feasible treatment option, particularly in patients refractory to lenalidomide.<\/jats:p>","DOI":"10.4143\/crt.2025.418","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T22:17:06Z","timestamp":1745533026000},"page":"320-328","update-policy":"https:\/\/doi.org\/10.4143\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Experience of Weekly Carfilzomib in Combination with Cyclophosphamide and Dexamethasone in Multiple Myeloma Relapsed\/Refractory to Bortezomib and Lenalidomide"],"prefix":"10.4143","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8699-8146","authenticated-orcid":true,"given":"Cheongin","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changgon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunye","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka-Won","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Hyun","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4289-3907","authenticated-orcid":true,"given":"Joon Seong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0054-3641","authenticated-orcid":true,"given":"Yoon Seok","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2954","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00135-5"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0003"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05701-3"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.247015"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01115-6"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.1035"},{"key":"ref7","first-page":"9","volume-title":"Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions","author":"Jung","year":"2025"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.206"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2018.11.007"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.740796"},{"key":"ref11","first-page":"142","volume-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","author":"Stewart","year":"2015"},{"key":"ref12","first-page":"27","volume-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","author":"Dimopoulos","year":"2016"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.76.5032"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01531-2"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s44313-025-00069-3"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.05.009"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00544-x"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00535-0"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(22)00350-7"},{"key":"ref20","first-page":"552","volume-title":"Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed\/refractory multiple myeloma: final results from the MCRN-003\/MYX.1 single arm phase II trial","author":"Venner","year":"2021"},{"key":"ref21","first-page":"2694","volume-title":"Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive)","author":"Yong","year":"2021"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13697"},{"key":"ref23","first-page":"2753","volume-title":"Randomized phase II study of weekly carfilzomib 70 mg\/m(2) and dexamethasone with or without cyclophosphamide in relapsed and\/or refractory multiple myeloma patients","author":"Puertas","year":"2023"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30354-1"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.327"},{"key":"ref26","first-page":"e328","volume-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","author":"Kumar","year":"2016"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25726"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1805111"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.02.004"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00849-z"}],"container-title":["Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2025-418.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2025.418","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2025-418.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T07:45:04Z","timestamp":1768203904000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2025.418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"URL":"https:\/\/doi.org\/10.4143\/crt.2025.418","relation":{},"ISSN":["1598-2998","2005-9256"],"issn-type":[{"value":"1598-2998","type":"print"},{"value":"2005-9256","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"assertion":[{"value":"2025-04-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-25","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-15","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}